title: Formulation, antimicrobial and toxicity evaluation of bioceramic based ofloxacin loaded biodegradable microspheres for periodontal infection.
abstract: In the present study an attempt has been made to load Poly (Lactic-Co-glycolic acid) microspheres with hydroxyapatite (HA) and ofloxacin and propose the composite microspheres to be used as local drug delivery system with the drug releasing capability for periodontitis treatment. A modified single emulsion method has been used for the preparation of microspheres. Experiments were conducted to optimize the formulation by RSM-Box-Behnken Method, which is an independent quadratic design involving three or four independent variables against a pre determined set of dependant parameters. The particle size of composite microspheres was analyzed and the average size was found to be 22.05 μm. Photomicrographs and scanning electron micrographs showed that the composite microspheres are spherical in shape and porous in nature. The microbiological activity of optimized formulation was evaluated using strain: S. aureus-ATCC- 29213 and E. coli-ATCC-25922. In vivo/in situ toxicity evaluation of the formulation was assessed by MTT assay and the formulation was found to be biocompatible.
authors: Department of Pharmaceutics, Jamia Hamdard, New Delhi, India.
authors: Tariq
authors: T
authors: Jamal
authors: Md Akhlaquer
authors: MA
authors: Rahman
authors: Mohd Aamir
authors: MA
authors: Mirza
authors: A K
authors: AK
authors: Panda
authors: Sushama
authors: S
authors: Talegaonkar
authors: Zeenat
authors: Z
authors: Iqbal
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004926:Escherichia coli / Q000187:drug effects* / Q000254:growth & development; D004927:Escherichia coli Infections; D019344:Lactic Acid / Q000737:chemistry; D051379:Mice; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D041681:NIH 3T3 Cells; D015242:Ofloxacin / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D010316:Particle Size; D010510:Periodontal Diseases; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013203:Staphylococcal Infections; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000900:Anti-Bacterial Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D015242:Ofloxacin